Asthma Clinical Trial
Official title:
Role of TLR4 in Environmental Asthma
The overall goal of this project is to identify genes that are involved in the development of airflow obstruction and airway inflammation in asthmatics, and to determine whether polymorphisms in these differentially expressed genes predispose individuals to develop asthma. In this project, we hypothesize that polymorphisms of genes expressed by the airway epithelia in asthmatics following specific airway challenges predispose individuals to the development of asthma.
The overall goal of this project is to identify genes that are involved in the development
of airflow obstruction and airway inflammation in asthmatics, and to determine whether
polymorphisms in these differentially expressed genes predispose individuals to develop
asthma. Asthma is a complex genetic disorder that is caused by a number of unique gene-gene
and gene-environment interactions. The search for asthma susceptibility genes has been
complicated by the broad clinical phenotype of asthma, the polygenic inheritance pattern of
this disease, and the substantial role of environmental exposures in the development and
progression of asthma. Inhaled environmental agents induce several biologic responses in
asthmatics; including the induction of acquired and innate immunity that leads to acute and
chronic forms of airway inflammation and airway remodeling. Acquired immune responses to
protein antigens, such as house dust mite allergen, often induce type 2 T lymphocyte-driven
responses (Th2) which appear to be important in atopic asthma. Recent studies by our group
and others demonstrate that innate immunity, initiated by inhalation of bacterial and viral
pathogens, organic dusts, endotoxin or lipopolysaccharide (LPS), air pollution particulate
matter, and ozone, can also cause acute and chronic forms of airflow obstruction, airway
inflammation, and even airway remodeling. Emerging evidence indicates that both acquired and
innate immune responses in the lung may be influenced by polymorphic genes. For instance,
functional polymorphisms in the IL-4 receptor gene are thought to preferentially stimulate
acquired Th2 immune responses to inhaled allergens, and we have recently shown that common
co-segregating mutations in TLR4 (a transmembrane receptor for LPS) are associated with
diminished airway responsiveness to inhaled LPS. These observations suggest that
environmental challenges can be used to narrow the phenotype of asthma and investigate
genetic susceptibility in biologically specific forms of asthma.
In this project, we hypothesize that polymorphisms of genes expressed by the airway
epithelia in asthmatics following specific airway challenges predispose individuals to the
development of asthma. To test this hypothesis, we plan to identify the genes that are
differentially expressed by airway epithelial cells following challenge with stimuli that
induce acquired (house dust mite) or innate (LPS) immune responses, and then determine
whether polymorphisms in these genes are associated with the development of asthma in a
separate, well characterized, familial cohort of asthmatics. This is a powerful approach
that is designed to identify novel genes that are associated with both asthma pathogenesis
(differentially expressed in the exposure-response study) and asthma susceptibility
(genetically associated with asthma in a linkage/association study).
We hypothesize that individuals with the co-segregating Asp299Gly and Thr399Ile mutations in
the TLR4 gene will exhibit a defective immune response to LPS, and that specific components
of altered immunity in these individuals are linked to characteristic airway responses to
LPS.
Specific Aim 1: Approximately 1000 individuals will be genotyped in order to establish 3
study groups: 10 subjects homozygous for the TLR4 299/399 mutation; 10 subjects heterozygous
for the TLR4 299/399 mutation; and 10 subjects homozygous for wild type TLR 4.
Specific Aim 2: Ten individuals with wild type TLR4, 10 individuals heterozygous for mutant
TLR4 and 10 individuals homozygous for mutant TLR4 will be phenotyped for airway
responsiveness to inhaled LPS.
Specific Aim 3: In vitro immune responses to LPS will be measured in peripheral blood
monocytes and PMNs from 10 individuals with wild type TLR4, 10 individuals heterozygous for
mutant TLR4 and 10 individuals homozygous for mutant TLR4.
Specific Aim 4: The in vivo immune response to inhaled LPS will be assessed in
bronchoalveolar lavage (BAL) fluid and cells, and airway endobronchial brush biopsy cells in
10 individuals with wild type TLR4, 10 individuals heterozygous for mutant TLR4 and 10
individuals homozygous for mutant TLR4.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|